By Fineline Cube 
Pharmaron Beijing Co., Ltd. (HKG: 3759), a leading integrated CRO and CDMO service provider, announced its unaudited interim results for the six months ended 30 June 2026. The company reported total revenue of approximately RMB 7.60 billion, a 17.9% year‑over‑year increase, with profit attributable to owners of the parent rising 7.0% to roughly RMB 750 million.
H1 2026 Financial Highlights
| Metric | H1 2026 | YoY Change |
|---|---|---|
| Total Revenue | ~RMB 7.60 billion | +17.9 % |
| Profit Attributable to Owners | ~RMB 750 million | +7.0 % |
| New Orders Booked | Surge >30 % vs. prior‑year H1 | – |
| FY2026 Revenue Guidance | Growth of ~15 %–20 % | – |
Segment Performance – All Three Core Businesses Grow
| Business Segment | H1 2026 Revenue | Share of Total |
|---|---|---|
| Laboratory Services | RMB 4.63 billion | ~61 % |
| CDMO Services | RMB 1.88 billion | ~25 % |
| Clinical Research Services | RMB 1.07 billion | ~14 % |
All three core business segments delivered growth during the period, underscoring the resilience of Pharmaron’s integrated CRO‑CDMO platform spanning drug discovery through commercial manufacturing.
Order Momentum & Management Outlook
- New Orders: Bookings surged over 30% year‑over‑year in the first half, signaling strengthening demand across the company’s service lines
- Guidance: Based on current order momentum and business trends, management expects full‑year 2026 revenue growth of approximately 15%–20%
- Implication: The guidance implies sustained acceleration in the second half, supported by the expanding order backlog
Market Impact & Outlook
- CRO Sector Recovery: The results reinforce signs of a broader rebound in outsourced R&D spending, as biopharma clients resume pipeline investment following the funding downcycle of recent years
- Integrated Platform Edge: Pharmaron’s ability to grow across Laboratory Services, CDMO, and Clinical Research simultaneously highlights the appeal of one‑stop providers to cost‑conscious sponsors
- Profit vs. Revenue Dynamics: Profit growth of 7.0% lagged revenue expansion of 17.9%, suggesting margin pressure or investment spending — a watch item for investors assessing second‑half profitability
- Visibility: With new orders up more than 30% and explicit full‑year guidance, Pharmaron offers rare forward visibility in the CRO sector
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Pharmaron’s revenue guidance, order momentum, and business outlook for 2026. Actual results may differ due to risks including client spending patterns, geopolitical and regulatory developments, and competitive pricing in the CRO and CDMO markets.-Fineline Info & Tech